Product Center
Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-25
- Views:
(Summary description)Recently, the clinical launch meeting for the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, in collaboration with Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by the Guangzhou Women and Children's Medical Center as the lead research unit, aiming to provide evidence-based influenza vaccination guidelines for children with nephrotic syndrome as a special population, thereby reducing their risk of influenza virus infection and severe complications.
Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held
(Summary description)Recently, the clinical launch meeting for the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, in collaboration with Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by the Guangzhou Women and Children's Medical Center as the lead research unit, aiming to provide evidence-based influenza vaccination guidelines for children with nephrotic syndrome as a special population, thereby reducing their risk of influenza virus infection and severe complications.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-25 09:46
- Views:
Recently, the clinical launch meeting for a study on the immunogenicity and safety of a quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, conducted in collaboration with Ab&B Bio-Tech Co., Ltd. (Ab&B Bio), was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by the Guangzhou Women and Children's Medical Center as the lead research unit, aiming to provide evidence-based influenza vaccination guidelines for children with nephrotic syndrome as a special population, thereby reducing their risk of influenza virus infection and severe complications.
This clinical study also represents an innovative exploration of the integrated medicine and prevention model, aiming to jointly promote disease prevention and control, improve the quality of medical services and healthcare technology capabilities, minimize the occurrence of health problems, manage the deterioration of health conditions effectively, and enhance the appropriateness and effectiveness of medical and health services to achieve patient-centered care.
Nephrotic syndrome is the most common glomerular disease in children. According to the Evidence-Based Guidelines for the Diagnosis and Treatment of Hormone-Sensitive, Recurrent/Dependent Nephrotic Syndrome in Children, the global annual incidence rate among children is 1.15 to 16.90 per 100,000. Due to its pathophysiological characteristics and the immunosuppressive treatment regimens, influenza virus infection increases the management difficulty and disease recurrence rate. Children with nephrotic syndrome experience impaired immune function due to long-term use of glucocorticoids and immunosuppressants. According to 2023 data from the Guangzhou Women and Children's Medical Center, the incidence of severe nephrotic syndrome cases complicated by influenza is as high as 43.67%, with a severity rate significantly higher (3% to 5%) than that in healthy children. Additionally, the recurrence rate of proteinuria after infection is as high as 56.8%. Therefore, enhancing influenza prevention for these children is particularly critical. Currently, there is limited research on influenza vaccination in children with nephrotic syndrome globally, and further exploration is needed regarding the safety profile and optimal vaccination strategies for this population.
The quadrivalent influenza virus subunit vaccine HRK-X, with its unique subunit production process technology, ensures that the key antigen components (hemagglutinin [HA] and neuraminidase [NA]) account for over 85% of the vaccine content. Its quality standards exceed those of the Chinese and European Pharmacopoeia, achieving international advanced levels, which ensures both safety and strong immunogenicity. This makes it particularly suitable for vulnerable populations, such as those with chronic diseases.
The integration of medicine and prevention is a foundational approach to establishing a high-quality, efficient health service system in China, and a key initiative to advance the Healthy China strategy. Health management services based on this integration are essential to ensure universal access to necessary, high-quality, and affordable healthcare, including prevention, treatment, rehabilitation, and health promotion.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
